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OBJECTIVE—To evaluate the long-term intervention effects of oral insulin on the develop-
mentoftype1diabetesandtoassesstherateofprogressiontotype1diabetesbeforeandafteroral
insulin treatment was stopped in the Diabetes Prevention Trial–Type 1 (DPT-1).
RESEARCH DESIGN AND METHODS—The follow-up included subjects who partic-
ipated in the early intervention of oral insulin (1994–2003) to prevent or delay type 1 diabetes.
A telephone survey was conducted in 2009 to determine whether diabetes had been diagnosed
and, if not, an oral glucose tolerance test (OGTT), hemoglobin A1c (HbA1c), and autoantibody
levels were obtained on all subjects who agreed to participate.
RESULTS—Of 372subjects randomized, 97 developed type 1diabetesbeforefollow-up; 75%
of the remaining 275 subjects were contacted. In the interim, 77 subjects had been diagnosed
withtype1diabetesand54oftheremainderhavehadanOGTT;10ofthesewerediagnosedwith
type 1 diabetes, subsequently. Among individuals meeting the original criteria for insulin auto-
antibodies (IAAs) ($80 nU/mL), the overall beneﬁt of oral insulin remained signiﬁcant (P =
0.05). However, the hazard rate in this group increased (from 6.4% [95% CI 4.5–9.1] to 10.0%
[7.1–14.1]) after cessation of therapy, which approximated the rate of individuals treated with
placebo (10.2% [7.1–14.6]).
CONCLUSIONS—Overall, the oral insulin treatment effect in individuals with conﬁrmed
IAA $80 nU/mL appeared to be maintained with additional follow-up; however, once therapy
stopped,therateofdevelopingdiabetesintheoralinsulingroupincreasedtoaratesimilartothat
in the placebo group.
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I
ntheDiabetesPreventionTrial–Type1
(DPT-1), conducted from 1994 to
2003, oral insulin or placebo was ad-
ministeredtononaffectedrelativesoftype
1 probands ascertained to have a 26–50%
risk of developing diabetes over a 5-year
period (1,2). In this trial, 103,391 rela-
tives of type 1 diabetic patients were
screened and 97,273 samples for anti-
bodies (Abs) were analyzed. There were
372 subjects enrolled and randomized.
After approximately one-third of the sub-
jects were recruited, the insulin autoanti-
body (IAA) entry criteria were lowered
from 80 to 39 nU/mL. At study end, there
was no beneﬁcial effect observed overall
(1). However, it was noted that oral insu-
lin resulted in a signiﬁcant delay in type 1
diabetes (P = 0.04) in individuals re-
cruitedbeforethechangeineligibilitycri-
teria (i.e., having an IAA level $80
nU/mL) and all those accrued who met
the original eligibility criteria (IAA level
$80 nU/mL) (P = 0.015); the annualized
type 1 diabetes rate was 6.2% during oral
insulin treatment and 10.4% with pla-
cebo, with a delay in diabetes progression
by 4.5 years (1).
In this follow-up study, we evaluated
thelong-termeffectsoforalinsulinonthe
development of type 1 diabetes and as-
sessed the rate of progression to type 1
diabetes before and after oral insulin
treatment was stopped.
RESEARCH DESIGN AND
METHODS—Screening, staging, and
randomizationofDPT-1subjectsandother
study methods have been described (1).
The original double-masked oral insulin
trial enrolled 372 subjects with a pro-
jected 5-year risk of diabetes of 26–50%
(60% male, 88% Caucasian, median age
10.3years)between1994and2002(me-
dian follow-up of 4.3 years). Participants
were randomly assigned to 7.5 mg oral in-
sulin or placebo intervention once a day.
Follow-up study
In 2009, the Type 1 Diabetes TrialNet
Network funded a follow-up study of the
DPT-1 oral insulin trial subjects to de-
termine whether the beneﬁcial effect was
prolonged. Each of the eight DPT-1 cen-
ters contacted those subjects eligible for
recontact on the basis of the following
criteria: 1) they were diabetes-free at time
oflastcontactand2)theyagreedtofuture
contact on the DPT-1 consent form. The
studywascompletedintwophases.Phase
1 consisted of a questionnaire follow-up
byphone to eligible subjects todetermine
current diabetes status, date of diagnosis,
diabetes treatment, symptoms at time of
diagnosis, most recent diabetes-associated
laboratory work before diagnosis, and
willingness to return for a clinical visit if
diabetes-free.Subjectswhowerediabetes-
free were eligible for phase 2, which con-
sisted of an in-person clinic visit for
a one-time oral glucose tolerance test
(OGTT) to assessglycemicstatus, hemoglo-
bin A1c (HbA1c), C-peptide, and Ab testing.
The protocol was approved by the
institutional review boards at participat-
ing locations, and all participants pro-
vided written informed consent.
Laboratory measures
All test procedures and assays performed
have been described (3). The TrialNet
biochemical antibody laboratory had
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ORIGINAL ARTICLEsensitivities and speciﬁcities of 76/99%
for GAD, 64/100% for islet cell antibody
(ICA)512, and 58/99% for micro-IAA
(mIAA) on the basis of the 2005 Diabetes
Antibody Standardization Program (4).
The OGTT includes samples for glucose
and C-peptide levels at 0, 30, 60, 90, and
120 min. HbA1c was measured in a single
reference laboratory.
Statistical analysis
Data were analyzed using the Statistical
Analysis System Software (version 9.2;
SAS Institute, Cary, NC). All variables not
normally distributed were log-transformed
for analysis. The area under the curve
(AUC) C-peptide was calculated using the
trapezoid rule. The intention-to-treat prin-
ciple was used for this analysis. Kaplan-
Meierlifetableswereusedtodeterminethe
time to type 1 diabetes onset by treatment
group and were compared using the log-
rank x
2 statistic. Categorical variables were
analyzed using Pearson x
2 tests or Fisher
exact test. Mean differences were tested us-
ing ANOVA. Data were summarized using
mean (SD) or median (interquartile range).
All tests for signiﬁcance were two-tailed.
Cox proportional hazards models were
used to estimate the risk for type 1 diabetes
by treatment adjustedfor time on study and
time since treatment ended.
RESULTS—Of the 372 subjects who
participated in the original DPT-1 study,
275 were eligible for the follow-up study;
97developedtype1diabetesatthe endof
the study in 2003 (0.02 [Q1–Q3: 0–0.5]
median years after treatment to type 1 di-
abetes diagnosis) (Fig. 1). Through the
2009 follow-up study, 206 (75%) of the
eligible subjects were contacted with
the median follow-up time of 9.1 years
(107 were on oral insulin and 99 were
on placebo). A total of 37% (n = 77) had
developed type 1 diabetes (median 3.7
[2.0–5.3] years after treatment to type 1
diabetes diagnosis); 71% (n = 92, 49 were
on oral insulin and 44 on placebo during
trial) of the 129 subjects diabetes-free on
contact agreed toa clinic visittocomplete
anOGTT,HbA1c,andAbtestingand59%
(n = 54) completed a follow-up clinic
visit. Of these (28 were on oral insulin
and 26 on placebo during the trial),
OGTT testing identiﬁed 26% (n =1 4 )
with impaired glucose tolerance, 11%
(n = 6) with asymptomatic type 1 diabe-
tes,and7%(n=4)withsymptomatictype
1 diabetes. There were no signiﬁcant
changes between baseline and follow-up
measures of HbA1c (P =0 . 9 9 ) ,G A D 6 5
positivity (P = 0.11), mIAA positivity
(P = 0.99), or ICA512 positivity (P =
0.43) in subjects who completed a follow-
upvisit.Signiﬁcantchangeswerenotedfor
mean C-peptide AUC during OGTT (base-
line AUC: 491 [SD 185]; follow-up AUC:
647 [SD 233], P , 0.0001) and ICA posi-
tivity (P , 0.0001), where all 54 subjects
were ICA positive at baseline and
19 (35%) reverted to being ICA negative
at the follow-up visit.
Over the entire study and follow-up,
individuals who did not develop type 1
diabetes (n = 198) had a signiﬁcantly
lower median ICA titer (80 vs. 160 Juve-
nile Diabetes Foundation Units, P ,
0.0001), lower mean IAA titer (309.3 vs.
426.5 nU/mL, P = 0.02), lower propor-
tion with ICA512 (45 vs. 60%, P =
0.004), higher mean ﬁrst-phase insulin
response (173.1 vs. 145.6 mU/mL, P =
0.002), higher mean C-peptide peak
(5.7 vs. 5.1 ng/mL, P = 0.003), higher
mean C-peptide AUC (530.1 vs. 470.7,
P = 0.005) measured by OGTT, were
more likely to be black or Hispanic
(10.5 vs. 4.5%, P = 0.03), and were older
at time of randomization in study (me-
dian age 11 vs. 9 years, P , 0.0001)com-
pared with individuals who developed
type 1 diabetes (n = 174).
Table 1 provides the baseline charac-
teristics at the time of randomization into
the DPT-1 study of the subjects eligible
for the follow-up study by whether or
not contact was achieved. Individuals
c o n t a c t e dw e r em o r el i k e l yt ob ew h i t e
(P , 0.0001) compared with those un-
able to be contacted.
Figure 2 shows the Kaplan-Meier
curve from the start of the DPT-1 to the
end of the follow-up for both the entire
oral insulin population (Fig. 2A, n =3 7 2 )
and subjects with a baseline conﬁrmed
IAA $80 nU/mL (Fig. 2B, n =2 6 3 ) .
The overall median follow-up was
Figure 1—Flow diagramofall subjectsrecruitedintothe originalDPT-1 studyand results of the
follow-up study. IVGTT, intravenous glucose tolerance test; T1D, type 1 diabetes.
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DPT-1 oral insulin trial follow-up9.1(Q1–Q3:8.7–10.1)years.Theannu-
alized rate of type 1 diabetes develop-
ment for the entire population was
7.4% per year in the oral insulin group
and 8.2% in the placebo group (hazard
ratio [HR] 1.125, 95% CI 0.837–1.511;
P=0.436).Insubjectswithabaselinecon-
ﬁrmed IAA level $80 nU/mL, the annual-
ized rate of type 1 diabetes development
was 7.7% per year in the oral insulin group
and 10.1% in the placebo group (HR 1.384,
95% CI 0.995–1.925; P = 0.052). Even af-
terdiscontinuingoralinsulintreatment,in-
dividuals with a conﬁrmed IAA level $80
nU/mL who received oral insulin appeared
to beneﬁt overall by signiﬁcantly delaying
type 1 diabetes onset by 2.2 years.
Figure3breaksdownthepatientsub-
groups with conﬁrmed IAAs $80 nU/mL
into the following: time on (all subjects
treated with oral insulin) and off (only
subjects contacted through the follow-
up) treatment for the oral insulin group
(Fig. 3A) and time on (monitored on
study receiving placebo) and off (only
subjects contacted through follow-up
and no longer monitored on study) treat-
ment for the placebo group (Fig. 3B).
There were 130 subjects who received
oral insulin during the study, and 97
(75%) of those subjects were contacted
in the follow-up; 133 subjects received
placebo and 85 (64%) were contacted in
the follow-up. The annualized rate of di-
abetes while on oral insulin was 6.2%;
after treatment ended, the rate increased
to 9.5%, a rate similar to the placebo
group (HR 1.492, 95% CI 0.911–2.444;
P = 0.110). Figure 3A clearly shows that
the reduced rate of diabetes development
depicted in Fig. 2 is only apparent during
thetimethesubjectsreceivedoralinsulin.
During the time on oral insulin compared
with after oral insulin treatment, type 1
diabetes onset was delayed by 3.9 years.
After oral insulin ended, the median esti-
mated survival for subjects treated was
similar to placeboduringtheoriginaltrial
(6.32 years for placebo vs. 6.94 years for
oral insulin after oral insulin treatment
ended). Figure 3B shows the proportion
of the placebo group without diabetes
while on study and off study. The annual
type 1 diabetes rate on study was 10.4%
and off study was 9.7% (HR 0.826, 95%
CI 0.513–1.330; P = 0.431). The hazard
rate remained relatively constant for sub-
jects in the placebo group over the study
and follow-up periods.
Figure 4A and B shows the propor-
tion of subjects diabetes-free in the
subgroup who did not have conﬁrmed
IAA $80 nU/mL for those who received
oral insulin (Fig. 4A) or placebo (Fig. 4B).
In Fig. 4A, the annualized type 1 diabetes
rateforthetimeonoralinsulinwas6.9and
4.5% during the follow-up time after ther-
apy was withdrawn (HR 0.817, 95% CI
0.330–2.022; P = 0.661). Figure 4B de-
scribes the proportion of subjects in the
placebo group diabetes-free both during
study and after study. The annualized rate
was 2.7% during the study and 4.2% after
study (HR 1.379, 95% CI 0.444–4.286;
P =0 . 5 7 7 ) .
CONCLUSIONS—The follow-up of
the DPT-1 study showed that level of
IAAtiterisassociatedwithresponsiveness
to oral insulin. The overall oral insulin
effect in individuals with conﬁrmed IAA
levels $80 nU/mL was maintained with
additional follow-up; however, once oral
insulin was stopped, the rate of develop-
ing diabetes in the oral insulin group be-
came similar to the rate in the placebo
group. This regression provides evidence
that subjects with IAA levels $80 nU/mL
who received oral insulin before type 1
diabetes onset have delayed progression
while on oral insulin, but once treatment
ended, the risk of type 1 diabetes in-
creased to the level observed in the pla-
cebo group. Because the loss of beneﬁt
coincided with the discontinued oral in-
sulin,itishypothesizedthattheimmuno-
logical effect is tied temporally to the
insulin intervention. In contrast, indi-
viduals with IAA levels ,80 nU/mL
displayed the opposite effect with a
Table 1—Baseline characteristics (at time of randomization) of subjects eligible for
follow-up study
Subjects contacted
in DPT-1
follow-up
Subjects unable
to contact in
DPT-1 follow-up P
n 206 69
Median age‡ 10 (7–14) 11 (8–16) 0.0962
Average ﬁrst-phase insulin
response (mU/mL)* 158.7 (93.6) 182.4 (75.2) 0.0574
Race† ,0.0001
White 193 (93.6) 52 (75.3)
African American 1 (0.4) 4 (5.8)
Hispanic 5 (2.4) 12 (17.3)
Other 7 (3.2) 1 (1.4)
Sex† 0.9082
Male 127 (61.6) 42 (60.8)
Female 79 (38.3) 27 (39.1)
Relationship to index patient
with diabetes† 0.1139
Sibling 108 (52.4) 47 (68.1)
Offspring 63 (30.5) 13 (18.8)
Parent 13 (6.3) 2 (2.9)
Second-degree relative 22 (10.6) 7 (10.1)
Antibody levels
Median ICA (Juvenile Diabetes
Foundation Units)‡ 80 (40–160) 40 (20–160) 0.1175
Mean IAA (nU/mL)* 329.59 (411.6) 349.48 (671.0) 0.7703
GAD antibodies† 0.8384
Positive 146 (74.9) 51 (76.1)
Negative 49 (25.1) 16 (23.9)
ICA512 antibodies† 0.5207
Positive 93 (47.7) 35 (52.2)
Negative 102 (52.3) 32 (47.8)
mIAA antibodies† 0.7028
Positive 13 (20.3) 6 (24.0)
Negative 51 (79.7) 19 (76.0)
HbA1c (%)* 5.31 (0.38) 5.36 (0.36) 0.3095
C-peptide AUC (during OGTT)* 505.77 (208.0) 532.75 (190.4) 0.3447
Data are *mean (SD), †n (%), or ‡median (interquartile range).
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Vehik and Associatesnonstatistically signiﬁcant increasing risk
of type 1 diabetes with oral insulin, while
similarly the effect is attenuated, once
therapy stopped.
The mechanism through which oral
insulin mediates the apparent treatment
response is unclear, but tolerance induc-
tion through this route may operate via
effects on the adaptive immune system
(5). Several nonclinical studies of the re-
sponse to oral antigen have identiﬁed the
induction of T cells that are associated
with, and can adoptively transfer, protec-
tion from autoimmune disease (6). These
cellsaretypicallyantigenspeciﬁc,areCD4
+,
secrete the immune suppressive cytokines
interleukin (IL)-10 and transforming
growth factor (TGF)-b (7,8), and have
been termed TH3 cells or regulatory T cells
(Tregs) (9). In other settings in which
antigen-induced tolerance was achieved
via a mucosal route (intranasal), there is
evidence of activation-induced cell death
of responder T cells (10), a possibility that
should be explored in future studies of
oral antigen administration. Preliminary
evidence has recently shown that these
processes could be counterproductive, at
least theoretically, if Tregs are also deleted
or sequestered (M. von Herrath, personal
communication) and that the balance of
induction/deletion is strongly inﬂuenced
bythedose(frequency),withmorefrequent
dosing being more harmful (11–13). A
further intriguing, and hitherto unex-
plained, ﬁnding of the oral insulin study
has been the reliance of the therapeutic
effect on the presence of high levels of
IAAs. It is possible that the mechanistic
pathway requires the induction of adap-
tive Tregs from cohorts of preexisting
insulin-speciﬁc T cells, or perhaps that
antigen presentation by insulin-speciﬁcB
cells is important (14). In summary, the
T-cell ﬁe l dh a sm a t u r e ds u f ﬁciently to
allow rational hypotheses as to the mech-
anistic effects of oral insulin to be pro-
posed and examined experimentally.
In previous mouse model studies,
such as those that inﬂuenced the initia-
tion of the DPT-1 study (15–17), oral in-
sulintherapywassuccessfulinpreventing
type 1 diabetes onset; however, therapy
was dose dependent, with a reduction in
insulitis seen at lower doses (1 mg), dis-
appearing at higher doses (5 mg) (18).
Although the majority of human studies
reported no beneﬁcial effect (1,19,20),
one study (21) that focused on evaluating
time of intervention, antigen dosing, and
administration interval reported that oral
insulin given in low doses (1 mg) delays
b-cell failure in new-onset patients .20
years of age. This double-blind placebo-
controlled study randomized 191 sub-
jects who were 5–60 years of age to
receive 1 mg insulin dose, 10 mg insulin
dose, or placebo. Ergun-Longmire et al.
(21) demonstrated that age and duration
of diabetes in combination with different
immunological and metabolic markers
have varying responsiveness to varying
doses of oral insulin. The addition of the
DPT-1 follow-up study ﬁnding that IAA
titer is associated with drug therapy re-
sponsiveness will have a considerable im-
pact on future human studies, such as
those with antigen-speciﬁc immunother-
apy, where understanding that variation
in biomarker levels may have a large im-
pact on immunotherapy success (22).
The results of the randomized clinical
trials designed to delay or prevent type 1
diabetes progression to date have indi-
cated that timing of intervention, dosing
and frequency, age at diagnosis, baseline
C-peptide level, and number and type of
Ab areimportantfactorsthat need further
investigation when designing effective
treatment interventions. This study of a
subgroupwithintheDPT-1studyprovided
new evidence that IAA titer affects respon-
siveness to oral insulin therapy. These re-
sults and advances in the immunological
ﬁeld(i.e.,antigen-speciﬁc immunotherapy)
using the TrialNet Network will provide
ample opportunity to retest this hypothesis
as well as others that evaluate varying dose
and frequency of oral insulin therapy,
evaluate other immunologic and metabolic
Figure2—A:Timetotype1diabetesfortheentireDPT-1populationfrom1994to2009.B:Time
totype1diabetesforsubjectswithabaselineIAAlevelconﬁrmed$80nU/mLfrom1994to2009.
(A high-quality color representation of this ﬁgure is available in the online issue.)
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DPT-1 oral insulin trial follow-upbiomarkers, and assess responsiveness to
drug therapy as a prevention strategy in
type 1 diabetes.
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